3 active not recruiting, 1 completed, 1 not yet recruiting. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Active not recruiting 3 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Bioferon: new trials by email Literature Review of Bioferon trials Research Report on Bioferon
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer Paclitaxel, Cisplatin, Bioferon - Ovarian Cancer | Phase 2 | Not yet recruiting | Kalinski, Pawel, MD, PhD | 28 | 2026-10-01 | 2026-10-13 |
| Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery Biospecimen Collection, Computed Tomography, Ipilimumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1301 | 2015-11-10 | 2026-10-01 |
| Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Ipilimumab, Laboratory Biomarker Analysis, Recombinant Interferon Alfa-2b - Recurrent Melanoma, Stage IIIA Cutaneous Melanoma AJCC v7 | Phase 2 | Completed | National Cancer Institute (NCI) | 88 | 2013-03-25 | 2026-07-21 |
| Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Ipilimumab, Quality-of-Life Assessment, Recombinant Interferon Alfa-2b - Melanoma of Unknown Primary, Recurrent Melanoma | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1673 | 2011-06-17 | 2026-10-22 |
| Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor Bevacizumab, Laboratory Biomarker Analysis, Octreotide Acetate - Colorectal Neuroendocrine Tumor G1, Gastric Neuroendocrine Tumor G1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 427 | 2007-12-01 | 2026-10-22 |
Melanoma (3) · Neuroendocrine Tumors (1) · Ovarian Neoplasms (1)
National Cancer Institute (NCI) (4) · Kalinski, Pawel, MD, PhD (1)
United States (5) · Canada (2) · Ireland (1)
Ahmad Tarhini (2) · James C Yao (1) · Robert Edwards, MD (1) · Sapna Patel (1)
PMID 25649350, PMID 28384065, PMID 35659704, PMID 36029412, PMID 36416836
U10CA021115 (2), U10CA180820 (2), U10CA180888 (2), U24CA196172 (2), P50CA121973 (1), U10CA032102 (1)